0.8584
9.64%
-0.0916
Pre-market:
.8399
-0.0185
-2.16%
Sunshine Biopharma Inc stock is currently priced at $0.8584, with a 24-hour trading volume of 5.01M.
It has seen a -9.64% decreased in the last 24 hours and a +1,319% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.9644 pivot point. If it approaches the $0.7387 support level, significant changes may occur.
Previous Close:
$0.95
Open:
$0.94
24h Volume:
5.01M
Market Cap:
$853.70K
Revenue:
$24.09M
Net Income/Loss:
$-4.51M
P/E Ratio:
-0.511
EPS:
-1.68
Net Cash Flow:
$-9.56M
1W Performance:
-40.39%
1M Performance:
+1,319%
6M Performance:
+168.33%
1Y Performance:
+37.19%
Sunshine Biopharma Inc Stock (SBFM) Company Profile
Name
Sunshine Biopharma Inc
Sector
Phone
-
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire
Sunshine Biopharma Inc Stock (SBFM) Latest News
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Dow Surges 200 Points; Abbott Laboratories Posts Upbeat Earnings
Benzinga
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Gold Jumps Over 2%; Wells Fargo Earnings Top Views
Benzinga
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Why the Risk With Penny Stocks is Worth the Reward
PennyStocks
Sunshine Biopharma Inc Stock (SBFM) Financials Data
Sunshine Biopharma Inc (SBFM) Revenue 2024
SBFM reported a revenue (TTM) of $24.09 million for the quarter ending December 31, 2023, a +454.42% rise year-over-year.
Sunshine Biopharma Inc (SBFM) Net Income 2024
SBFM net income (TTM) was -$4.51 million for the quarter ending December 31, 2023, a +83.15% increase year-over-year.
Sunshine Biopharma Inc (SBFM) Cash Flow 2024
SBFM recorded a free cash flow (TTM) of -$9.56 million for the quarter ending December 31, 2023, a -82.21% decrease year-over-year.
Sunshine Biopharma Inc (SBFM) Earnings per Share 2024
SBFM earnings per share (TTM) was -$0.197 for the quarter ending December 31, 2023, a +89.32% growth year-over-year.
About Sunshine Biopharma Inc
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Cap:
|
Volume (24h):